Athena Countouriotis insider trades

Open-market stock purchases and sales by Athena Countouriotis, Director at Iovance Biotherapeutics, Inc, from SEC Form 4 filings since Jul 16, 2013.

Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -79%.

Recent trades

DateStockTradeValue
Jun 16, 2026IOVA Iovance Biotherapeutics, IncBought (not open market)—
Jun 2, 2026BMRN Biomarin Pharmaceutical IncBought (not open market)—
May 19, 2026PASG Passage BIO, IncBought (not open market)—

Companies traded

  • IOVA Iovance Biotherapeutics, Inc: other filings, last Jun 16, 2026
  • BMRN Biomarin Pharmaceutical Inc: other filings, last Jun 2, 2026
  • PASG Passage BIO, Inc: 2 buys, last May 19, 2026
  • TPTX Turning Point Therapeutics, Inc: 3 buys, 14 sales, last Aug 17, 2022
  • TROV Trovagene, Inc: other filings, last Jun 20, 2019
  • ADVM Adverum Biotechnologies, Inc: other filings, last Feb 15, 2018
  • HALO Halozyme Therapeutics Inc: other filings, last Feb 22, 2017
  • AMBI Ambit Biosciences Corp: other filings, last Nov 10, 2014

Get free alerts when Athena Countouriotis files a new trade →